findmyKOL

Matthew Zibelman, MD

Basic profile

Fox Chase Cancer Center

ORCID↗NPI↗
RegionPhiladelphia, PA · NortheastSpecialtyMedical OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Matthew Zibelman is an Oncology physician affiliated with Fox Chase Cancer Center. OpenAlex indexes 268 publications with 2,443 citations (h-index 28); ClinicalTrials.gov lists 2 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
268publications

Distinct works indexed by OpenAlex, matched via ORCID.

2,443citations

Total citations across indexed works.

28h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials ↓
18companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

333 Cottman Ave
Philadelphia, PA 191112434

Telephone

215-728-2500

Registry record last updated 8 Jun 2016.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

25 more payment records behind the reveal.Reveal →
View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    49.5%
    Cytochrome P450 17A1 Inhibitor28.3%
    Abiraterone Acetate94%Zytiga6%
    Part D<11 patients
    Gonadotropin Releasing Hormone Receptor Antagonist8.2%
    Orgovyx100%
    Part D≥23 patients

    + 4 more classes in this area

  • Metabolism & gastrointestinal

    36.5%
    Corticosteroid32.2%
    Prednisone100%
    Part D≥86 patients
    Serotonin-3 Receptor Antagonist4.3%
    Ondansetron Hcl100%
    Part D≥37 patients

  • Nervous system

    7.3%
    SNRI2.2%
    Venlafaxine Hcl Er100%
    Part D<11 patients
    Atypical Antipsychotic1.5%
    Olanzapine100%
    Part D≥12 patients

    + 3 more classes in this area

Where care is delivered (Part B)90.2% facility · 9.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

45 more publications behind the reveal.Reveal →

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”